Cogent Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COGT research report →
Companywww.cogentbio.com
Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
- CEO
- Andrew R. Robbins
- IPO
- 2018
- Employees
- 205
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $5.63B
- P/E
- -6.26
- P/S
- 0.00
- P/B
- 3.65
- EV/EBITDA
- -15.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -83.29%
- ROIC
- -42.77%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-328,937,000 · -28.56%
- EPS
- $-2.55 · -3.66%
- Op Income
- $-333,363,000
- FCF YoY
- -27.66%
Performance & Tape
- 52W High
- $43.73
- 52W Low
- $4.75
- 50D MA
- $35.60
- 200D MA
- $28.84
- Beta
- 0.37
- Avg Volume
- 2.02M
Get TickerSpark's AI analysis on COGT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Ferrante Karen Jean | other | 686 |
| Mar 31, 26 | Fairmount Funds Management LLC | other | 7,000,000 |
| Mar 31, 26 | Fairmount Funds Management LLC | sell | 7,000,000 |
| Mar 31, 26 | Fairmount Funds Management LLC | other | 28,000 |
| Jan 22, 26 | Fairmount Funds Management LLC | sell | 3,500,000 |
| Jan 1, 26 | Ferrante Karen Jean | other | 643 |
| Dec 26, 25 | Kearns Evan | sell | 65,000 |
| Dec 26, 25 | Green John L. | sell | 77,000 |
| Dec 26, 25 | Sachs Jessica | sell | 82,642 |
| Dec 26, 25 | Robinson John Edward | sell | 90,000 |
Our COGT Coverage
We haven't published any research on COGT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate COGT Report →